These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 25721307)

  • 1. A phase II trial of AZD1152 in relapsed/refractory diffuse large B-cell lymphoma.
    Collins GP; Eyre TA; Linton KM; Radford J; Vallance GD; Soilleux E; Hatton C
    Br J Haematol; 2015 Sep; 170(6):886-90. PubMed ID: 25721307
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors.
    Boss DS; Witteveen PO; van der Sar J; Lolkema MP; Voest EE; Stockman PK; Ataman O; Wilson D; Das S; Schellens JH
    Ann Oncol; 2011 Feb; 22(2):431-7. PubMed ID: 20924078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia.
    Kantarjian HM; Martinelli G; Jabbour EJ; Quintás-Cardama A; Ando K; Bay JO; Wei A; Gröpper S; Papayannidis C; Owen K; Pike L; Schmitt N; Stockman PK; Giagounidis A;
    Cancer; 2013 Jul; 119(14):2611-9. PubMed ID: 23605952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
    Flinn IW; Bartlett NL; Blum KA; Ardeshna KM; LaCasce AS; Flowers CR; Shustov AR; Thress KS; Mitchell P; Zheng F; Skolnik JM; Friedberg JW
    Eur J Cancer; 2016 Feb; 54():11-17. PubMed ID: 26707592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significance of AZD1152 as a potential treatment against Aurora B overexpression in acute promyelocytic leukemia.
    Ghanizadeh-Vesali S; Zekri A; Zaker F; Zaghal A; Yousefi M; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
    Ann Hematol; 2016 Jun; 95(7):1031-42. PubMed ID: 27091351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia.
    Löwenberg B; Muus P; Ossenkoppele G; Rousselot P; Cahn JY; Ifrah N; Martinelli G; Amadori S; Berman E; Sonneveld P; Jongen-Lavrencic M; Rigaudeau S; Stockman P; Goudie A; Faderl S; Jabbour E; Kantarjian H
    Blood; 2011 Dec; 118(23):6030-6. PubMed ID: 21976672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia.
    Tsuboi K; Yokozawa T; Sakura T; Watanabe T; Fujisawa S; Yamauchi T; Uike N; Ando K; Kihara R; Tobinai K; Asou H; Hotta T; Miyawaki S
    Leuk Res; 2011 Oct; 35(10):1384-9. PubMed ID: 21565405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia.
    Dennis M; Davies M; Oliver S; D'Souza R; Pike L; Stockman P
    Cancer Chemother Pharmacol; 2012 Sep; 70(3):461-9. PubMed ID: 22864876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152).
    Keizer RJ; Zandvliet AS; Beijnen JH; Schellens JH; Huitema AD
    Invest New Drugs; 2012 Aug; 30(4):1519-30. PubMed ID: 21626115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ofatumumab monotherapy in relapsed/refractory diffuse large B-cell non-Hodgkin lymphoma.
    Galanina N; Jasielec J; Peace D; Smith SM; Nabhan C
    Leuk Lymphoma; 2017 Mar; 58(3):752-753. PubMed ID: 27415580
    [No Abstract]   [Full Text] [Related]  

  • 11. Copanlisib: First Global Approval.
    Markham A
    Drugs; 2017 Dec; 77(18):2057-2062. PubMed ID: 29127587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma.
    Robertson MJ; Kahl BS; Vose JM; de Vos S; Laughlin M; Flynn PJ; Rowland K; Cruz JC; Goldberg SL; Musib L; Darstein C; Enas N; Kutok JL; Aster JC; Neuberg D; Savage KJ; LaCasce A; Thornton D; Slapak CA; Shipp MA
    J Clin Oncol; 2007 May; 25(13):1741-6. PubMed ID: 17389337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Everolimus in diffuse large B-cell lymphomas.
    Merli M; Ferrario A; Maffioli M; Arcaini L; Passamonti F
    Future Oncol; 2015; 11(3):373-83. PubMed ID: 25675120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic polymeric nanoparticles and the methods of making and using thereof: a patent evaluation of WO2015036792.
    Sarvagalla S; Hsieh HP; Coumar MS
    Expert Opin Ther Pat; 2016 Jul; 26(7):751-5. PubMed ID: 27167102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype.
    Hernandez-Ilizaliturri FJ; Deeb G; Zinzani PL; Pileri SA; Malik F; Macon WR; Goy A; Witzig TE; Czuczman MS
    Cancer; 2011 Nov; 117(22):5058-66. PubMed ID: 21495023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 2 trial of alisertib in patients with relapsed or refractory B-cellnon-Hodgkin lymphoma.
    Cohen JB; Maddocks KJ; Huang Y; Christian BA; Jaglowski SM; Flowers CR; Blum KA
    Leuk Lymphoma; 2017 Sep; 58(9):1-2. PubMed ID: 28278718
    [No Abstract]   [Full Text] [Related]  

  • 17. Modeling Dose and Schedule Effects of AZD2811 Nanoparticles Targeting Aurora B Kinase for Treatment of Diffuse Large B-cell Lymphoma.
    Floc'h N; Ashton S; Ferguson D; Taylor P; Carnevalli LS; Hughes AM; Harris E; Hattersley M; Wen S; Curtis NJ; Pilling JE; Young LA; Maratea K; Pease EJ; Barry ST
    Mol Cancer Ther; 2019 May; 18(5):909-919. PubMed ID: 30872381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma.
    Brander D; Rizzieri D; Gockerman J; Diehl L; Shea TC; Decastro C; Moore JO; Beaven A
    Leuk Lymphoma; 2013 Dec; 54(12):2627-30. PubMed ID: 23488610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Copanlisib (Aliqopa) for relapsed follicular lymphoma.
    Med Lett Drugs Ther; 2018 Apr; 60(1545):e74-e75. PubMed ID: 29667951
    [No Abstract]   [Full Text] [Related]  

  • 20. An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma.
    Burke JM; Shustov A; Essell J; Patel-Donnelly D; Yang J; Chen R; Ye W; Shi W; Assouline S; Sharman J
    Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):e327-e331. PubMed ID: 29934062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.